ÂÜÀòÂÒÂ×

Dr. Boyle has over 25 years of pharmaceutical and biotechnology industry experience including leadership roles in private start-up and multinational companies. Dr. Boyle was most recently President of VivaMab, a drug development division of BioAtla involved in the discovery and development of therapeutic antibodies. Prior to that he was President and Chief Science Officer at Anaptysbio, and former Director of Research at Amgen, Inc. where he led the discovery and early preclinical development of Denosumab, a RANKL-targeted therapeutic antibody. Dr. Boyle holds a Doctoral degree in Experimental Pathology from the UCLA School of Medicine, and was a Howard Hughes Medical Institute Postdoctoral Fellow of the Life Sciences Research Foundation at the Salk Institute in La Jolla. He also currently serves on the Board of Directors for Alethia Biotherapeutics, a biotechnology company focused on new treatments for ovarian cancer.